HomeAI · summaries
Storia in 4 fonti
After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed confidence ahead of its hi | Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma, a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed confidence ahead of its high-stakes first-line readout.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell…
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- ·
fiercepharma.com
After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed…
- ·
benzinga.com
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - AbbVie (NYSE:ABBV)
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.
- ·
endpoints.news
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
AbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse…